| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $917,286 ) |
| | 2023 | 2023 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 001 | 13 | NIH | 7/7/2023 | $152,051 |
| | 2023 | 2023 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 13 | NIH | 10/1/2022 | -$91,957 |
| | 2023 | 2023 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 003 | 10 | NIH | 7/31/2023 | $1,824,315 |
| | 2023 | 2022 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 9 | NIH | 10/24/2022 | $0 |
| | 2023 | 2021 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 002 | 8 | NIH | 12/29/2022 | $0 |
| | 2023 | 2018 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 5 | NIH | 10/1/2022 | -$967,123 |
|
| Issue Date FY: 2022 ( Subtotal = $1,901,480 ) |
| | 2022 | 2022 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 12 | NIH | 7/1/2022 | $153,075 |
| | 2022 | 2022 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 9 | NIH | 7/19/2022 | $1,748,405 |
|
| Issue Date FY: 2021 ( Subtotal = $1,908,595 ) |
| | 2021 | 2021 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 11 | NIH | 6/17/2021 | $154,100 |
| | 2021 | 2021 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 8 | NIH | 7/20/2021 | $1,754,495 |
|
| Issue Date FY: 2020 ( Subtotal = $1,647,836 ) |
| | 2020 | 2020 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 002 | 7 | NIH | 7/31/2020 | $1,492,637 |
| | 2020 | 2020 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 10 | NIH | 6/9/2020 | $155,199 |
| | 2020 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 6 | NIH | 7/29/2020 | $678,797 |
| | 2020 | 2018 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 5 | NIH | 7/29/2020 | -$678,797 |
|
| Issue Date FY: 2019 ( Subtotal = $1,418,349 ) |
| | 2019 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 9 | NIH | 6/13/2019 | $156,263 |
| | 2019 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 6 | NIH | 8/9/2019 | $800,419 |
| | 2019 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 6 | NIH | 8/16/2019 | $800,419 |
| | 2019 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 6 | NIH | 8/16/2019 | -$800,419 |
| | 2019 | 2019 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 002 | 6 | NIH | 9/9/2019 | $461,667 |
|
| Issue Date FY: 2018 ( Subtotal = $1,670,634 ) |
| | 2018 | 2018 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 8 | NIH | 6/16/2018 | $149,563 |
| | 2018 | 2018 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 5 | NIH | 7/31/2018 | $1,041,899 |
| | 2018 | 2018 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 5 | NIH | 9/17/2018 | $479,172 |
|
| Issue Date FY: 2017 ( Subtotal = $1,454,729 ) |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 001 | 7 | NIH | 8/22/2017 | -$150,674 |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 002 | 4 | NIH | 9/14/2017 | $440,000 |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 000 | 7 | NIH | 7/28/2017 | $150,674 |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 4 | NIH | 7/31/2017 | $819,883 |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1HL109526 | Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia. | 001 | 7 | NIH | 8/22/2017 | $150,674 |
| | 2017 | 2017 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 001 | 4 | NIH | 8/14/2017 | $44,172 |
| | 2017 | 2016 | NORTHSIDE HOSPITAL, INC. | 1000 JOHNSON FERRY RD | ATLANTA | GA | 30342-1606 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 6 | NIH | 7/14/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,145,887 ) |
| | 2016 | 2016 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 3 | NIH | 7/29/2016 | $1,045,219 |
| | 2016 | 2016 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 6 | NIH | 2/26/2016 | $100,668 |
|
| Issue Date FY: 2015 ( Subtotal = $1,274,328 ) |
| | 2015 | 2015 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 2 | NIH | 9/3/2015 | $1,170,828 |
| | 2015 | 2015 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 5 | NIH | 5/11/2015 | $103,500 |
|
| Issue Date FY: 2014 ( Subtotal = $1,274,328 ) |
| | 2014 | 2014 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 4 | NIH | 5/24/2014 | $103,500 |
| | 2014 | 2014 | NORTHSIDE HOSPITAL INC | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | UG1CA189997 | Georgia NCI Community Oncology Research Program (GA NCORP) | 000 | 1 | NIH | 7/31/2014 | $1,170,828 |
|
| Issue Date FY: 2013 ( Subtotal = $103,500 ) |
| | 2013 | 2013 | NORTHSIDE HOSPITAL | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 001 | 3 | NIH | 8/8/2013 | $4,968 |
| | 2013 | 2013 | NORTHSIDE HOSPITAL | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 3 | NIH | 6/11/2013 | $98,532 |
|
| Issue Date FY: 2012 ( Subtotal = $103,500 ) |
| | 2012 | 2012 | NORTHSIDE HOSPITAL | 1000 JOHNSON FERRY ROAD NE | ATLANTA | GA | 30342 | FULTON | USA | U10HL109526 | Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD | 000 | 2 | NIH | 6/8/2012 | $103,500 |
|
|
